Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pneumonia, Ventilator-Associated

Conditions

Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Abdominal Abscess, Bacterial Infections

Trial Timeline

Oct 1, 2007 → Nov 1, 2008

NCT ID

NCT00515034

About Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem

Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem is a phase 2 stage product being developed by Johnson & Johnson for Pneumonia, Ventilator-Associated. The current trial status is completed. This product is registered under clinical trial identifier NCT00515034. Target conditions include Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia.

What happened to similar drugs?

20 of 20 similar drugs in Pneumonia, Ventilator-Associated were approved

Approved (20) Terminated (4) Active (0)

✅doripenemJohnson & JohnsonApproved

✅Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved

✅Imipenem + ImipenemMerckApproved

✅Ceftolozane / Tazobactam InjectionMerckApproved

✅ceftriaxoneRocheApproved

✅Zavicefta, Ceftazidime-AvibactamPfizerApproved

✅Vancomycin + LinezolidPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00515034	Phase 2	Completed	Oct 1, 2007	Nov 1, 2008	Pneumonia, Ventilator-Associated

Competing Products

20 competing products in Pneumonia, Ventilator-Associated

See all competitors

Product	Company	Stage	Hype Score
CAL02 Low-dose + CAL02 High-dose + Placebo	Combioxin	Phase 1	19
tacrolimus	Astellas Pharma	Pre-clinical	26
Cefiderocol + Best Available Therapy	Shionogi	Phase 3	40
Cefiderocol + Meropenem + Linezolid	Shionogi	Phase 3	40
Cefiderocol + Standard of Care Antibiotic	Shionogi	Phase 1	21
ONO-5046Na + ONO-5046Na	Ono Pharmaceutical	Phase 2	35
doripenem	Johnson & Johnson	Approved	43
levofloxacin; imipenem/cilastitin	Johnson & Johnson	Phase 3	40
levofloxacin	Johnson & Johnson	Phase 3	40
levofloxacin	Johnson & Johnson	Phase 2/3	38
Levofloxacin	Johnson & Johnson	Phase 3	40
doripenem	Johnson & Johnson	Phase 3	40
doripenem	Johnson & Johnson	Phase 3	40
Doripenem + Imipenem-Cilastatin + Placebo	Johnson & Johnson	Phase 3	32
HRS-8427 + Meropenem	Jiangsu Hengrui Medicine	Phase 2	42
Ceftazidime-avibactam	AbbVie	Phase 1	21
Ticagrelor + Placebo	AstraZeneca	Phase 2	27
Tedizolid phosphate + Linezolid	Merck	Phase 3	40
Ceftolozane/Tazobactam + Piperacillin/Tazobactam	Merck	Phase 3	32
IMI/REL FDC + PIP/TAZ FDC + Linezolid	Merck	Phase 3	40